[Form 4] Vita Coco Company, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Charles van Es, Chief Sales Officer of Vita Coco Company, Inc. (COCO), reported transactions dated 09/12/2025 on Form 4. He exercised a stock option to acquire 10,000 shares at an exercise price of $10.178 per share and simultaneously sold 10,000 shares under a Rule 10b5-1 plan at a weighted average price of $40.002 per share. After these transactions his beneficial ownership is reported as 84,328 shares. The filing itemizes multiple outstanding non-qualified stock options with exercise prices ranging from $10.178 to $33.36 and various vesting schedules; some options are fully vested and exercisable. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 09/16/2025.

Positive

• Exercise and sale executed transparently: Sale reported as made pursuant to a Rule 10b5-1 trading plan.
• Realized spread disclosed: Exercise price of $10.178 and weighted average sale price of $40.002 for 10,000 shares, explicitly reported.
• Clear option schedule: Multiple non-qualified stock options and vesting schedules are itemized, improving disclosure of potential future dilution.

Negative

• Reduction in insider holdings: Beneficial ownership decreased by 10,000 shares to 84,328 shares following the sale.
• Outstanding option pool remains: Significant numbers of options remain exercisable or subject to future vesting, which could lead to dilution if exercised.

Insights

Financial Analyst

TL;DR: Officer exercised options at $10.178 and sold shares at ~$40.00 via a 10b5-1 plan, reducing holdings but realizing a material spread.

The reported exercise and concurrent sale are typical compensation monetization events. The exercise price of $10.178 and weighted average sale price of $40.002 are explicitly stated, indicating a significant per-share spread between exercise and sale prices for the 10,000 shares transacted. The filing also discloses a portfolio of outstanding non-qualified options with staggered vesting and expiration dates, which could lead to future option exercises and potential share issuances if exercised. No new material corporate developments or changes in control are reported.

Corporate Governance Expert

TL;DR: Transactions follow standard insider protocols, with sales executed under a Rule 10b5-1 plan and attorney-in-fact signature on the Form 4.

The sale being executed pursuant to a Rule 10b5-1 trading plan and the Form 4 being signed by counsel are both procedural safeguards that reduce concerns about opportunistic insider trading. The filing clearly lists vesting schedules for multiple option grants, including several fully vested options, providing transparency on future potential insider issuance. No departures, repricings, or unusual governance actions are disclosed.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

van Es Charles

(Last) (First) (Middle)

250 PARK AVE SOUTH

SEVENTH FLOOR

(Street)

NEW YORK NY 10003

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Vita Coco Company, Inc. [ COCO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Sales Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/12/2025		M		10,000	A	$10.178	94,328	D
Common Stock	09/12/2025		S(1)		10,000	D	$40.002(2)	84,328	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (right to buy)	$10.178	09/12/2025		M			10,000	(3)	02/10/2030	Common Stock	10,000	$0.0	93,750	D
Non-Qualified Stock Option (right to buy)	$10.178							(4)	01/11/2031	Common Stock	27,300		27,300	D
Non-Qualified Stock Option (right to buy)	$15							(5)	10/21/2031	Common Stock	58,043		58,043	D
Non-Qualified Stock Option (right to buy)	$15.36							(6)	08/15/2032	Common Stock	42,980		42,980	D
Non-Qualified Stock Option (right to buy)	$16.91							(7)	03/10/2033	Common Stock	14,205		14,205	D
Non-Qualified Stock Option (right to buy)	$26.18							(8)	03/04/2034	Common Stock	8,746		8,746	D
Non-Qualified Stock Option (right to buy)	$33.36							(9)	03/04/2035	Common Stock	13,218		13,218	D

Explanation of Responses:

1. The sales of shares of common stock reported were effected pursuant to a Rule 10b5-1 trading plan.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.03, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

3. The stock option is fully vested and currently exercisable.

4. The stock option is fully vested and currently exercisable.

5. The stock option vests in four equal annual installments beginning on November 27, 2022.

6. The stock option vests in three equal annual installments beginning on August 15, 2025.

7. The stock option vests in four equal annual installments beginning on March 10, 2024.

8. The stock option vests in four equal annual installments beginning on March 4, 2025.

9. The Reporting Person was granted stock options that will vest in four annual equal installments on each anniversary of the grant date provided that the Reporting Person remains in continuous service on each vesting date.

	By: Alison Klein, Attorney-in-Fact For: Charles Van Es	09/16/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many shares does Charles van Es beneficially own after the transactions in Form 4 for COCO?

The filing reports 84,328 shares beneficially owned following the reported transactions.

At what price were the 10,000 shares sold by the reporting person in the COCO Form 4?

The shares were sold at a weighted average price of $40.002 per share under a Rule 10b5-1 plan; individual sale prices ranged from $40.00 to $40.03.

What was the exercise price for the option exercised on 09/12/2025 in the COCO filing?

The exercised option had an exercise price of $10.178 per share for 10,000 shares.

Were the sales in the Form 4 for COCO part of a pre-established trading plan?

Yes, the filing states the sales were effected pursuant to a Rule 10b5-1 trading plan.

Does the Form 4 disclose other outstanding options for the reporting person at COCO?

Yes, the Form 4 lists multiple non-qualified stock options with exercise prices from $10.178 to $33.36 and various vesting schedules and expirations.